| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
|
Purity: ≥98%
| ln Vitro |
In vitro, ligands' capacity to induce NFκB RAGE activation in cancer cells is diminished by the RAGE antagonist peptide TFA [1].
|
|---|---|
| ln Vivo |
In PDAC cells, RAGE-mediated basal NFκB activity is inhibited in vivo by RAGE antagonist peptide TFA (100 μg) [1]. Glioma growth can be inhibited and pancreatic tumor growth and metastasis can be decreased by RAGE antagonist peptide TFA [1]. The RAGE antagonist peptide TFA (RAP; 4 mg/kg; ip) decreased the release of Th2 cytokines and attenuated goblet cell metaplasia, airway inflammation, and airway responsiveness in mice with asthma. Additionally, RAGE antagonist peptide TFA can decrease β-catenin's total, cytoplasmic, and nuclear levels; increase β-catenin Ser33/37/Thr41 phosphorylation, which in turn causes ubiquitination; suppress β-catenin target gene expression; and prefer β-catenin to be retained at the cell membrane, which transforms β-catenin from an active mode of signaling to an adhesive function [2].
|
| Animal Protocol |
Animal/Disease Models: Cancer cells expressing the NFκB-luc reporter implanted into immune-deficient mice[1].
Doses: 100 µg Route of Administration: Intratumoral delivery (or intraperitoneally (ip)). Experimental Results: Systemic administration caused a substantial reduction (p<0.05) in the NFκB signal 5 h after injection. |
| References |
| Molecular Formula |
C59H102F3N13O19S
|
|---|---|
| Molecular Weight |
1386.58
|
| Related CAS # |
RAGE antagonist peptide;1092460-91-7
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~25 mg/mL (~18.03 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7212 mL | 3.6060 mL | 7.2120 mL | |
| 5 mM | 0.1442 mL | 0.7212 mL | 1.4424 mL | |
| 10 mM | 0.0721 mL | 0.3606 mL | 0.7212 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA